Indivior Pharmaceuticals Inc
Indivior Pharmaceuticals Inc（INDV）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · INDV · 截至 2026年6月8日
活动摘要
买入笔数
8
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Indivior Pharmaceuticals Inc内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
INDV 季度内部人买卖趋势
INDV 内幕交易卖出 · INDV 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · INDV CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
INDV 高管卖出股份 · INDV 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 13, 2026 | Thompson Juliet Director | Award | 6,518 | — | Form 4 |
| May 12, 2026 | Thompson Juliet Director | Other | 1,117 | $43K | Form 4 |
| May 13, 2026 | Humphreys Keith Director | Award | 6,518 | — | Form 4 |
| May 13, 2026 | Kingsley Stuart A Director | Award | 6,518 | — | Form 4 |
| May 13, 2026 | NINIVAGGI DANIEL A Director | Award | 6,518 | — | Form 4 |
| May 13, 2026 | Ryan Barbara Director | Award | 6,518 | — | Form 4 |
| May 13, 2026 | Stejbach Mark Director | Award | 6,518 | — | Form 4 |
| May 13, 2026 | Wheadon David E. Director | Award | 10,430 | — | Form 4 |
| Mar 14, 2026 | Preblick Ryan CFO | Option | 6,302 | — | Form 4 |
| Mar 14, 2026 | Preblick Ryan CFO | Other | 2,843 | $88K | Form 4 |
| Mar 13, 2026 | Ryan Barbara Director | Purchase | 8 | $249 | Form 4 |
| Mar 6, 2026 | Kingsley Stuart A Director | Purchase | 940 | $30K | Form 4 |
| Mar 9, 2026 | Ryan Barbara Director | Purchase | 31 | $1K | Form 4 |
| Mar 3, 2026 | Anderson Woodrow D CAO | Option | 18,364 | — | Form 4 |
| Mar 3, 2026 | Anderson Woodrow D CAO | Option | 5,946 | — | Form 4 |
| Mar 3, 2026 | Anderson Woodrow D CAO | Other | 2,682 | $86K | Form 4 |
| Mar 3, 2026 | Anderson Woodrow D CAO | Other | 8,283 | $265K | Form 4 |
| Mar 3, 2026 | Preblick Ryan CFO | Option | 86,949 | — | Form 4 |
| Mar 3, 2026 | Preblick Ryan CFO | Other | 87,597 | $2.80M⚡ | Form 4 |
| Mar 3, 2026 | Burris Jeffrey W Chief Legal Officer | Option | 79,893 | — | Form 4 |
| Mar 3, 2026 | Burris Jeffrey W Chief Legal Officer | Other | 36,032 | $1.15M⚡ | Form 4 |
| Mar 3, 2026 | Heidbreder Christian Chief Scientific Officer | Option | 101,544 | — | Form 4 |
| Mar 3, 2026 | Heidbreder Christian Chief Scientific Officer | Other | 45,797 | $1.46M⚡ | Form 4 |
| Feb 10, 2026 | Anderson Woodrow D CAO | Award | 6,903 | — | Form 4 |
| Feb 10, 2026 | Preblick Ryan CFO | Award | 37,358 | — | Form 4 |
Heidbreder Christian
Chief Scientific Officer
日期
Mar 3
股数
45,797
均价
$31.98
总金额
$1.46M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 INDV 内幕交易
INDV 内幕交易
Indivior Pharmaceuticals Inc（INDV）内幕交易数据来源于公司内部人（包括Preblick Ryan (CFO), Anderson Woodrow D (CAO), Ryan Barbara (Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。INDV内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Indivior Pharmaceuticals Inc机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
INDV 内幕交易 · 5个问题Indivior Pharmaceuticals Inc（INDV）的内部人包括高管和董事，如Preblick Ryan (CFO), Anderson Woodrow D (CAO), Ryan Barbara (Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026